Bilal Bashira,b ∙ See Kwoka ∙ Anthony S. Wierzbickic ∙ Alan Jonesd ∙ Charlotte Dawsone ∙ Paul Downief,g ∙ Fiona Jenkinsonh∙ Hannah Delaneyi ∙ Michael Mansfieldj ∙ Dev Dattak ∙ Yee Teohl ∙ Paul Hamiltonm,n ∙ Natalie Forrestero ∙ Dawn O’Sullivanp ∙ Maryam Ferdousia ∙ Paul N. Durringtona ∙ Alaa AbdelRazikq ∙ Antonio Gallor,s ∙ Philippe Moulint ∙ Handrean Sorana,b Abstract Background and aims Prognosis and management differ between familial chylomicronaemia syndrome (FCS), a rare autosomal recessive disorder, and multifactorial chylomicronaemia syndrome (MCS) or severe mixed hyperlipidaemia. A clinical scoring tool to differentiate these conditions has been devised but not been validated in other populations. The objective of this study was to…

A UK Expert Panel Opinion Piece Introduction Familial chylomicronaemia syndrome (FCS) is a rare autosomal recessive disorder with an estimated prevalence of 1–2 per million, which equates to 55–110 people in England.1, 2 FCS is characterised by severe fasting hypertriglyceridaemia (HTG), defined as triglyceride (TG) concentrations >10 mmol/L (885 mg/dL) by the European Atherosclerosis Society Consensus…